{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:42:16Z","timestamp":1788835336361,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.radonc.2025.111258","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T16:00:17Z","timestamp":1762012817000},"page":"111258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Bridging radiotherapy for chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma: Systematic review and meta-analysis"],"prefix":"10.1016","volume":"214","author":[{"given":"Eric Ka-Ming","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai Yee","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-6890","authenticated-orcid":false,"given":"Kwok Keung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben Man-Fei","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111258_b0005","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111258_b0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.semradonc.2024.10.005","article-title":"The role of radiotherapy in lymphoma patients undergoing CAR T therapy: past, present, and future","volume":"35","author":"Wallington","year":"2025","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111258_b0015","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jcyt.2022.03.009","article-title":"Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma","volume":"24","author":"Sun","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.radonc.2025.111258_b0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/CJI.0000000000000284","article-title":"Radiation priming chimeric antigen receptor T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma with high tumor burden","volume":"43","author":"Qu","year":"2020","journal-title":"J Immunother"},{"key":"10.1016\/j.radonc.2025.111258_b0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.17738","article-title":"The impact of bridging therapy prior to CD19\u2010directed chimeric antigen receptor T\u2010cell therapy in patients with large B\u2010cell lymphoma","volume":"195","author":"Lutfi","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.radonc.2025.111258_b0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.radonc.2022.10.018","article-title":"Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed\/refractory aggressive B-cell lymphoma","volume":"177","author":"Yu","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111258_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109580","article-title":"Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy","volume":"183","author":"Fan","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111258_b0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41409-024-02427-8","article-title":"Role of bridging RT in relapsed\/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study","volume":"60","author":"Bramanti","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.radonc.2025.111258_b0045","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1182\/bloodadvances.2024013393","article-title":"CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas","volume":"8","author":"Cederquist","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.radonc.2025.111258_b0050","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1182\/bloodadvances.2024013647","article-title":"Outcomes of patients with R\/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy","volume":"8","author":"Saifi","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.radonc.2025.111258_b0055","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.19453","article-title":"Outcome and feasibility of radiotherapy bridging in large B\u2010cell lymphoma patients receiving CD19 CAR T in the UK","volume":"205","author":"Kuhnl","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.radonc.2025.111258_b0060","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/bloodadvances.2023011489","article-title":"Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium","volume":"8","author":"Jain","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.radonc.2025.111258_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1481080","article-title":"Hyper-fractionated radiotherapy as a bridging strategy to enhance CAR-T efficacy by regulating T-cell co-stimulatory molecules in relapsed\/refractory diffuse large B-cell lymphoma","volume":"15","author":"Ruan","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.radonc.2025.111258_b0070","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00432-024-05765-8","article-title":"Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed\/refractory large B-cell lymphoma: findings from a German monocentric study","volume":"150","author":"Eigendorff","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111258_b0075","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/curroncol32030173","article-title":"Enhancing CAR-T efficacy in large B-cell lymphoma with radiation bridging therapy: a real-world single-center experience","volume":"32","author":"Laverdure","year":"2025","journal-title":"Curr Oncol"},{"key":"10.1016\/j.radonc.2025.111258_b0080","doi-asserted-by":"crossref","unstructured":"Yegya-Raman N, Plastaras JP, Wright CM, et al. Bridging radiotherapy prior to chimeric antigen receptor T-cells for B-cell lymphomas: an ILROG multicenter study Blood Advances. Published online April 9, 2025:bloodadvances.2025015855. doi:10.1182\/bloodadvances.2025015855.","DOI":"10.1182\/bloodadvances.2025015855"},{"key":"10.1016\/j.radonc.2025.111258_b0085","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ijrobp.2025.03.023","article-title":"5-5-5 ABRT (dose of 5 Gy per fraction for up to 5 fractions over 5 weeks adaptive bridging radiation Therapy)\u2014artificial intelligence enters the CAR (-T) (chimeric antigen receptor-T) in relapsed\/refractory large B cell lymphoma","volume":"122","author":"Ababneh","year":"2025","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.radonc.2025.111258_b0090","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00277-025-06378-y","article-title":"Whole brain radiotherapy combined with CART-cell therapy for relapsed\/refractory central nervous system B-cell lymphoma","volume":"104","author":"Shi","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.radonc.2025.111258_b0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.111258_b0100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.111258_b0105","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.111258_b0110","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.radonc.2025.111258_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.radonc.2025.111258_b0120","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ijrobp.2022.12.017","article-title":"Don\u2019t put the CART before the horse: the role of radiation therapy in Peri-CAR T-cell therapy for aggressive B-cell non-hodgkin lymphoma","volume":"116","author":"Saifi","year":"2023","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.radonc.2025.111258_b0125","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamaoncol.2024.1113","article-title":"Comprehensive bridging radiotherapy for limited Pre-CART non-hodgkin lymphoma","volume":"10","author":"Saifi","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.111258_b0130","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3390\/cancers15061747","article-title":"Long-term follow-up of bridging therapies prior to CAR T-Cell therapy for relapsed\/refractory large B cell lymphoma","volume":"15","author":"Ladbury","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2025.111258_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1419788","article-title":"Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapy","volume":"15","author":"Ladbury","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.radonc.2025.111258_b0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jamaoncol.2023.4504","article-title":"Implications of high tumor burden on chimeric antigen receptor T-cell immunotherapy: a review","volume":"10","author":"Ventin","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.111258_b0145","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","article-title":"Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma","volume":"30","author":"Hubbeling","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.111258_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-023-00895-7","article-title":"Metabolic PET\/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity","volume":"13","author":"Breen","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.radonc.2025.111258_b0155","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell therapy: Cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.radonc.2025.111258_b0160","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474086.2022.2147919","article-title":"Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes","volume":"15","author":"Figura","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.radonc.2025.111258_b0165","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","article-title":"Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?","volume":"166","author":"Saifi","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111258_b0170","doi-asserted-by":"crossref","unstructured":"Imber BS, Brosoff A, Roszak E, et al. A proof-of-principle of split-course bridging radiotherapy (SC-BRT) prior to CAR T-cell therapies for relapsed or refractory B-cell lymphomas: A phase 1a pilot cohort. doi: 10.1182\/blood-2024-210156.","DOI":"10.1182\/blood-2024-210156"},{"key":"10.1016\/j.radonc.2025.111258_b0175","doi-asserted-by":"crossref","unstructured":"D\u2019Angelo CR, Enke C, Vose JM, et al. A prospective clinical trial of boom-boom radiation as bridging therapy for patients with large B-cell lymphoma undergoing treatment with Lisocabtagene Maraleucel (Liso-cel) Therapy. doi:10.1182\/blood-2024-208472.","DOI":"10.1182\/blood-2024-208472"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:29:59Z","timestamp":1786537799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025052624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"alternative-id":["S0167814025052624"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111258","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging radiotherapy for chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma: Systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111258"}}